Dermatol. praxi. 2022;16(3):139-144 | DOI: 10.36290/der.2022.027

Primary vasculitides in dermatological practice

doc. MUDr. Radim Bečvář, CSc.
Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha

By term "vasculitis" inflammatory disease of blood vessels is designated that leads to vessel wall destruction followed by proliferation and occlusion of their lumina. Basic condition for this diagnosis is that vessel wall is a primary site of the pathological process. Clinical syndromes are a consequence of this process resulting into ischaemia of tissues supplied by the affected vessels and with constitutional symptoms associated to the inflammatory disease. Vasculitis can occur de novo as a primary involvement of vessel wall of unknown aetiology or it develops secondary to other diseases. The diagnosis of vasculitis is usually based on pathological findings from biopsy or abnormalities detected by imaging methods. This review describes the common primary vasculitides with cutaneous manifestations, their diagnostics and management.

Keywords: vasculitis, arteritis, angiography, biopsy, immunosuppression.

Accepted: October 11, 2022; Published: October 17, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bečvář R. Primary vasculitides in dermatological practice. Dermatol. praxi. 2022;16(3):139-144. doi: 10.36290/der.2022.027.
Download citation

References

  1. Bečvář R, Tesař V, Rychlík I. Vaskulitidy v klinické praxi - diagnostika a terapie. Praha: Medprint; 1994.
  2. Ansell BM, Bacon PA, Lie JT, Yazici H. The vasculitides. Science and practice. London: Chapman&Hall Medical; 1996. Go to original source...
  3. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1. Go to original source... Go to PubMed...
  4. Fessler BJ. Approach to the diagnosis of vasculitis in adult patients. In: Ball GV, Louis Bridge S Jr, editors. Vasculitis, Oxford: Oxford University Press; 2008: p. 277-284.
  5. De Virgilio A, Greco A, Magliulo G, et al. Polyarteritis nodosa: A contemporary overview. Autoimmun Rev 2016(6); 15:564-570. Go to original source... Go to PubMed...
  6. Pagnoux C, Seror R, Henegar C for the French Vasculitis Study Group. Clinical Features and Outcomes in 348 Patients With Polyarteritis Nodosa A Systematic Retrospective Study of Patients Diagnosed Between 1963 and 2005 and Entered Into the French Vasculitis Study Group Database. Arthritis Rheum 2010;62(2):616-662. Go to original source... Go to PubMed...
  7. Henegar C, Pagnoux C, Puéchal X for the French Vasculitis Study Group. A paradigm of diagnostic criteria for polyarteritis nodosa: analysis of a series of 949 patients with vasculitides. Arthritis Rheum 2008;58(5):1528-1538. Go to original source... Go to PubMed...
  8. Guillevin L, Pagnoux C, Teixeira L. Treatment of PAN. In: Ball GV, Louis Bridges S Jr, editors. Vasculitis. Oxford: Oxford University Press; 2008: p. 347-349.
  9. Hoffman GS, Weyand CM, et al. Inflammatory diseases of blood vessels. New York: Marcel Dekker, Inc, 2002.
  10. Clain JM, Hummel AM, Stone JH, et al. Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis. Clin Exp Immunol 2017;188(1):174-181. Go to original source... Go to PubMed...
  11. Nikkari S, Mertsola J, Korvenranta H, et al. Wegener's granulomatosis and parvovirus B19 infection. Arthritis Rheum 1994;38(11):1707-1708. Go to original source... Go to PubMed...
  12. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116(6):488-498. Go to original source... Go to PubMed...
  13. Csernok E, Holle J, Hellmich B, et al. Evaluation of capture ELISA for detection of neutrophil cytoplasmic antibodies directed against proteinase 3 in Wegeners granulomatosis: first results from a multicenter study. Rheumatology (Oxford) 2004;43(2):174-180. Go to original source... Go to PubMed...
  14. Smith RM, Jones RB, Jayne DR. Progress in treatment of ANCA-associated vasculitis. Arthritis Res Ther 2012;4(2):210-213. Go to original source... Go to PubMed...
  15. Specks U. Churg-Strauss syndrome In: Ball GV, Louis Bridges S Jr, editors. Vasculitis. Oxford: Oxford University Press; 2008: p. 429-438.
  16. Zhou XL, Zheng MJ, Shuai ZW, et al. The significances of peripheral neutrophils CD(55) and myeloperoxidase expression in patients with myeloperoxidase-specific anti-neutrophil cytoplasmic antibody associated vasculitis. Zhonghua Nei Ke Za Zhi. 2017;56(6):427-432.
  17. Bečvář R. Moderní terapie ANCA pozitivních vaskulitid. Acta medicinae 2013;2:76-79.
  18. Fresko I, Melikoglu M, Kural-Seyahi E, et al. Behçet'syndrome: pathogenesis, clinical manifestations, and treatment. In: Ball GV, Louis Bridges S Jr, editors. Vasculitis. Oxford: Oxford University Press; 2008:461-474.
  19. International Study Group for Behçets disease. Criteria for diagnosis of Behcet's disease. Lancet 1990;335(8697):1078-1080. Go to original source...
  20. Hatemi G, Silman A, Bang D and EULAR Expert Committee. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67(12):1656-1662. Go to original source... Go to PubMed...
  21. Calvino MC, Llorca J, Garcia-Porrú AC, et al. Henoch-Schönlein purpura in childern in north western Spain: a 20-year epidemiologic and clinical study. Medicine (Baltimore) 2001;80(5):279-290. Go to original source... Go to PubMed...
  22. Ozen S, Marks SD, Brogan P, et al. European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative. Rheumatology (Oxford). 2019;58(9):1607-1616. Go to original source... Go to PubMed...
  23. Bogdanović R. Henoch-Schönlein purpura nephritis in children: risk factors, prevention and treatment. Acta Paediatr 2009;98(12):1882-1889. Go to original source... Go to PubMed...




Dermatology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.